CD200 and Miyoshi myopathy: A recently completed Phase I trial assessed treatment responses of CLL and MM patients to samalizumab, a humanized anti-CD200 monoclonal antibody designed to block CD200-CD200R binding while minimizing cytotoxicity to CD200-expressing immune cell subsets (by using an IgG region with limited effector function) [51].